Market Access News | pharmaphorum

News

Merus grabs first-in-class US approval for NRG1 cancer drug

Merus has its first approval for a commercial product, getting the go-ahead from the FDA for Bizengri, a first-in-class therapy for cancer

News

Mounjaro cleared for NHS use, but patients may have to wait

Many patients can expect a long wait for access to Eli Lilly's obesity shot Mounjaro, even though it has been recommended for routine NHS use by NICE

News

syringe being filled by hand with vaccine

UK orders 5 million bird flu jabs for pandemic preparedness

The UKHSA has taken steps to prepare for a possible bird flu outbreak by placing an order with Seqirus for millions of H5 vaccine doses.

News

MHRA's stature undermined by lack of resources says pharma

The MHRA isn't sufficiently funded to meet its obligations and that could threaten UK investment in life sciences, according to an ABPI report.

News

Warning letter adds to Applied Tx run of bad news

Applied Therapeutics gets a warning letter from the FDA over a trial of rare disease drug govorestat, which was rejected by the agency last week.

News

Cytokinetics' president and chief executive Robert Blum

FDA kicks off review of Cytokinetics' aficamten for HCM

Cytokinetics should hear back from the FDA next September about its application for Camzyos rival aficamten in obstructive hypertrophic cardiomyopathy

Merus grabs first-in-class US approval for NRG1 cancer drug

Mounjaro cleared for NHS use, but patients may have to wait

UK orders 5 million bird flu jabs for pandemic preparedness

MHRA's stature undermined by lack of resources says pharma

Warning letter adds to Applied Tx run of bad news

FDA kicks off review of Cytokinetics' aficamten for HCM

Amazon puts $100m into global health drive

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks